NICE has developed diagnostics guidance on Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia. Diagnostics guidance is designed to help the NHS adopt efficient and cost-effective diagnostic technologies more rapidly and efficiently.
NICE has said that Elucigene FH20 and LIPOchip are not recommended for confirming familial hypercholesterolaemia because another test called comprehensive genetic analysis is more likely to accurately confirm the diagnosis at a reasonable cost.
NICE has also said that Elucigene FH20 and LIPOchip are not recommended for testing relatives of people with familial hypercholesterolaemia. Another test called targeted sequencing is more likely to accurately detect familial hypercholesterolaemia in these relatives and is less expensive.